<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ruxolitinib (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ruxolitinib (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ruxolitinib (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="132788" href="/d/html/132788.html" rel="external">see "Ruxolitinib (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="132817" href="/d/html/132817.html" rel="external">see "Ruxolitinib (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56222867"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Jakafi</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56222973"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Jakavi</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F56223139"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Janus Associated Kinase Inhibitor</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Tyrosine Kinase Inhibitor</span>;</li>
<li>
<span class="list-set-name">Janus Associated Kinase Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F56222911"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0d15741b-9ba4-4dca-be19-0e3e27e469f7">Graft-versus-host disease, acute, steroid refractory, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease (GVHD), acute, steroid refractory, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fixed dosing: </i>Children ≥12 years and Adolescents: Oral: Initial: 5 mg twice daily. Consider increasing the dose to 10 mg twice daily after at least 3 days of treatment if ANC and platelets are not decreased by ≥50% compared to baseline (first day of ruxolitinib).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing: </i>Children and Adolescents: Limited data available: Oral: <b>Note:</b> Dosing based on a retrospective study of 13 patients (aged 1.6 to 16.5 years) receiving ruxolitinib for steroid-refractory GVHD. Ruxolitinib was associated with a high incidence of reversible adverse effects and fair overall response rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28344057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28344057'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;25 kg: Initial: 2.5 mg twice daily; if tolerated, may double the dose on a weekly basis to a maximum dose of 10 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥25 kg: Initial: 5 mg twice daily; if tolerated, may double the dose on a weekly basis to a maximum dose of 10 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Tapering of therapy:</i></b> Consider tapering ruxolitinib after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued; taper by 1 dose level approximately every 8 weeks (ie, 10 mg twice daily to 5 mg twice daily to 5 mg once daily). Consider retreatment if acute GVHD signs or symptoms recur during or after tapering ruxolitinib.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eed92e31-34ff-4472-a5e1-b9797e58e616">Graft-versus-host disease, chronic, refractory, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease (GVHD), chronic, refractory, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 10 mg twice daily; adjust as necessary for adverse effects (see "Dosing Adjustment for Toxicity").</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Tapering of therapy: </i></b>Consider tapering ruxolitinib after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued; taper by 1 dose level approximately every 8 weeks (ie, 10 mg twice daily to 5 mg twice daily to 5 mg once daily). Consider retreatment if chronic GVHD signs/symptoms recur during or after tapering ruxolitinib.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for toxicity: </b>Children ≥12 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute graft-versus-host disease:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Dosage reduction levels:</b></i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Dosage reduction is based on ruxolitinib regimen at time of toxicity.</p>
<p style="text-indent:-2em;margin-left:8em;">If dose is 10 mg twice daily, reduce dose to 5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">If dose is 5 mg twice daily, reduce dose to 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">If dose is 5 mg once daily, interrupt ruxolitinib treatment until clinical and/or laboratory parameters recover.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Dosage modification for hematologic toxicity:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">Clinically significant thrombocytopenia: Reduce dose by 1 dose level; when platelets recover to previous values, may increase dose to prior dose level.</p>
<p style="text-indent:-2em;margin-left:8em;">ANC &lt;1,000/mm<sup>3</sup> related to ruxolitinib treatment: Interrupt treatment for up to 14 days; upon recovery, restart at 1 dose level lower.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic graft-versus-host disease:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Dosage reduction levels:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">If dose is 10 mg twice daily, reduce dose to 5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">If dose is 5 mg twice daily, reduce dose to 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">If unable to tolerate 5 mg once daily, interrupt ruxolitinib treatment until clinical and/or laboratory parameters recover.</p>
<table border="1" frame="border" rules="all" style="margin-left:10em;">
<caption>
<b>Ruxolitinib Dosage Adjustment for Toxicity in Chronic GVHD</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Adverse Reaction</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Ruxolitinib Dosing Recommendation</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">
<b>
<i>Hematologic toxicity</i></b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Platelets &lt;20,000/mm<sup>3</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Reduce ruxolitinib by 1 dose level. If resolved within 7 days, may increase dose to initial dose level. If not resolved within 7 days, then maintain dose at 1 dose level lower than initial dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">ANC &lt;750/mm<sup>3</sup> (if considered related to ruxolitinib)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Reduce ruxolitinib by 1 dose level; resume at initial dose level upon recovery.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">ANC &lt;500/mm<sup>3</sup> (if considered related to ruxolitinib)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hold ruxolitinib for up to 14 days; resume at 1 dose level lower upon recovery. May resume initial dose level when ANC &gt;1,000/mm<sup>3</sup>.</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">
<b>
<i>Other adverse reactions (excluding hepatotoxicity)</i></b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Continue ruxolitinib at 1 dose level lower until recovery.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Discontinue ruxolitinib.</p></td></tr></tbody></table></div>
<div class="block dorp drugH1Div" id="F56222846"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥12 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease (GVHD); acute/steroid-refractory, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 59 mL/minute and any platelet count: Initial: 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Dialysis: Ruxolitinib not removed by dialysis, effect on metabolites unknown.</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease (ESRD) (CrCl &lt;15 mL/minute) on dialysis and any platelet count: Initial: 5 mg once after dialysis; monitor closely for safety and efficacy and make additional dose adjustments as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD (CrCl &lt;15 mL/minute) not requiring dialysis: Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease (GVHD); chronic, refractory, treatment</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 59 mL/minute and any platelet count: Initial: 5 mg twice daily. Additional dose adjustments should be made with frequent monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD (CrCl &lt;15 mL/minute) on dialysis and any platelet count: Initial dose: 10 mg once after dialysis; additional dose adjustments should be made with careful monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD (CrCl &lt;15 mL/minute) not requiring dialysis: Avoid use.</p></div>
<div class="block dohp drugH1Div" id="F56222844"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥12 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease (GVHD); acute/steroid-refractory, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Dosage reduction levels:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Dosage reduction is based on ruxolitinib regimen at time of toxicity.</p>
<p style="text-indent:-2em;margin-left:6em;">If dose is 10 mg twice daily, reduce dose to 5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">If dose is 5 mg twice daily, reduce dose to 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">If dose is 5 mg once daily, interrupt ruxolitinib treatment until clinical and/or laboratory parameters recover.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Hepatic impairment prior to initiation (baseline): </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Mild to severe hepatic impairment (based on NCI criteria) without liver acute graft-versus-host disease (aGVHD) and any platelet count: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Stage 1, 2, or 3 liver aGVHD and any platelet count: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Stage 4 liver aGVHD and any platelet count: Reduce dose to 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Hepatoxicity during treatment:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Total bilirubin elevation <b>without</b> liver GVHD</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">Total bilirubin 3 to 5 times ULN: Reduce dose by 1 dose level until total bilirubin recovers.</p>
<p style="text-indent:-2em;margin-left:8em;">Total bilirubin &gt;5 to 10 times ULN: Interrupt ruxolitinib treatment for up to 14 days; when bilirubin recovers to ≤1.5 times ULN, may restart at current dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Total bilirubin &gt;10 times ULN: Interrupt ruxolitinib treatment for up to 14 days; when bilirubin recovers to ≤1.5 times ULN, may restart at 1 dose level lower.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Total bilirubin elevation <b>with</b> liver GVHD</i>: Total bilirubin &gt;3 times ULN: Reduce dose 1 dose level until total bilirubin recovers.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease (GVHD); chronic, refractory, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Dosage reduction levels:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">If dose is 10 mg twice daily, reduce dose to 5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">If dose is 5 mg twice daily, reduce dose to 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">If unable to tolerate 5 mg once daily, interrupt ruxolitinib treatment until clinical and/or laboratory parameters recover.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Hepatic impairment prior to initiation (baseline):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Mild to severe impairment (based on NCI criteria) without liver chronic graft-versus-host disease (cGVHD) and any platelet count: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Score 1 or 2 liver cGVHD and any platelet count: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Score 3 liver cGVHD and any platelet count: Monitor blood counts more frequently for toxicity and modify the ruxolitinib dose for adverse reactions if they occur.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Hepatoxicity during treatment</i></b>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Total bilirubin 3 to 5 times ULN: Continue ruxolitinib at 1 dose level lower until recovery. If resolved within 14 days, then increase by 1 dose level. If not resolved within 14 days, maintain the decreased dose level.</p>
<p style="text-indent:-2em;margin-left:6em;">Total bilirubin &gt;5 to 10 times ULN: Interrupt ruxolitinib treatment for up to 14 days until resolved, then resume at the current dose upon recovery. If not resolved within 14 days, then resume at 1 dose level lower upon recovery.</p>
<p style="text-indent:-2em;margin-left:6em;">Total bilirubin &gt;10 times ULN: Interrupt ruxolitinib treatment for up to 14 days until resolved, then resume at 1 dose level lower upon recovery. If not resolved within 14 days, discontinue ruxolitinib.</p></div>
<div class="block doa drugH1Div" id="F56222910"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="132788" href="/d/html/132788.html" rel="external">see "Ruxolitinib (systemic): Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> If appropriate, utilize prophylactic antibiotics according to clinical practice guidelines. Delay initiating ruxolitinib until after active infections have resolved. If discontinuing ruxolitinib for reasons other than thrombocytopenia, consider gradually tapering off (by 5 mg twice daily each week).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0d15741b-9ba4-4dca-be19-0e3e27e469f7">Graft-versus-host disease, acute, steroid refractory, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease, acute, steroid refractory, treatment:</b>
<b>Oral:</b> Initial: 5 mg twice daily. Consider increasing the dose to 10 mg twice daily after at least 3 days of treatment (if ANC and platelets are not decreased by ≥50% compared to baseline [first day of ruxolitinib]).</p>
<p style="text-indent:-2em;margin-left:4em;">Consider tapering ruxolitinib after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued; taper by one dose level approximately every 8 weeks (10 mg twice daily to 5 mg twice daily to 5 mg once daily). Consider retreatment if acute graft-versus-host disease (GVHD) signs/symptoms recur during or after tapering ruxolitinib.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing:</i>
<b>Oral:</b> Initial: 10 mg twice daily (may continue calcineurin inhibitor and glucocorticoid therapy with ruxolitinib); in patients who respond, may begin tapering off after 56 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32320566']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32320566'])">Ref</a></span>). Refer to protocol for dosage adjustment and tapering recommendations.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eed92e31-34ff-4472-a5e1-b9797e58e616">Graft-versus-host disease, chronic, refractory, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease, chronic, refractory, treatment: Oral:</b> Initial: 10 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34260836','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34260836','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Consider tapering ruxolitinib after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued; taper by one dose level approximately every 8 weeks (10 mg twice daily to 5 mg twice daily to 5 mg once daily). Consider retreatment if chronic GVHD signs/symptoms recur during or after tapering ruxolitinib.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="02c97b93-892c-472e-b905-d7209fa55a9f">Myelofibrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myelofibrosis:</b> Initial dose (based on platelet count, titrate dose thereafter based on efficacy and safety):</p>
<p style="text-indent:-2em;margin-left:4em;">Platelets &gt;200,000/mm<sup>3</sup>: <b>Oral:</b> 20 mg twice daily</p>
<p style="text-indent:-2em;margin-left:4em;">Platelets 100,000 to 200,000/mm<sup>3</sup>: <b>Oral: </b>15 mg twice daily</p>
<p style="text-indent:-2em;margin-left:4em;">Platelets 50,000 to &lt;100,000/mm<sup>3</sup>: <b>Oral: </b>5 mg twice daily</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage modification based on response in patients with baseline platelet count ≥100,000/mm<sup>3</sup> prior to initial treatment with ruxolitinib:</b> For insufficient response (with adequate platelet and neutrophil counts), may increase the dose in 5 mg twice daily increments to a maximum dose of 25 mg twice daily. Do not increase during initial 4 weeks and no more frequently than every 2 weeks. Discontinue treatment after 6 months if no reduction in spleen size or no improvement in symptoms. When discontinuing for reasons other than thrombocytopenia, consider gradually tapering by ~5 mg twice daily per week.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dose increases may be considered if meet all of the following situations:</i></p>
<p style="text-indent:-2em;margin-left:8em;">- Failure to achieve either a 50% reduction (from baseline) in palpable spleen length or a 35% reduction (from baseline) in spleen volume (measured by CT or MRI)</p>
<p style="text-indent:-2em;margin-left:8em;">- Platelet count &gt;125,000/mm<sup>3</sup> at 4 weeks (and never &lt;100,000/mm<sup>3</sup>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Absolute neutrophil count (ANC) &gt;750/mm<sup>3</sup></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage modification for bleeding requiring intervention (regardless of platelet count):</b> Interrupt treatment until bleeding resolved; may consider resuming at the prior dose if the underlying cause of bleeding has resolved or at a reduced dose if the underlying cause of bleeding persists.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage modification based on response in patients with baseline platelet 50,000 to &lt;100,000/mm<sup>3</sup> prior to initial treatment with ruxolitinib: </b>For insufficient response (with adequate platelet and neutrophil counts), may increase the dose in 5 mg daily increments to a maximum dose of 10 mg twice daily. Do not increase during initial 4 weeks and no more frequently than every 2 weeks. Discontinue treatment after 6 months if no reduction in spleen size or no improvement in symptoms.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dose increases may be considered if meet all of the following situations:</i></p>
<p style="text-indent:-2em;margin-left:8em;">- Platelet count remains ≥40,000/mm<sup>3</sup> and did not decrease more than 20% in prior 4 weeks</p>
<p style="text-indent:-2em;margin-left:8em;">- Absolute neutrophil count (ANC) &gt;1,000/mm<sup>3</sup></p>
<p style="text-indent:-2em;margin-left:8em;">- No adverse event or hematological toxicity resulting in dose reduction or interruption occurred in prior 4 weeks</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="106b8731-242b-49a2-9174-21d0fbc9d21f">Polycythemia vera</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Polycythemia vera:</b>
<b>Oral:</b> Initial dose: 10 mg twice daily (titrate dose based on efficacy and safety)</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dose modification due to insufficient response:</b> If response is insufficient and platelet, hemoglobin, and neutrophil counts are adequate, the dose may be increased in 5 mg twice daily increments to a maximum of 25 mg twice daily. Do not increase dose in the first 4 weeks of treatment and not more frequently than every 2 weeks. Consider dose increases in patients who meet all of the following conditions:</p>
<p style="text-indent:-2em;margin-left:6em;">- Inadequate efficacy demonstrated by one or more of the following: Continued need for phlebotomy, WBC &gt;ULN of normal range, platelet count &gt;ULN of normal range, or palpable spleen that is reduced by &lt;25% from baseline.</p>
<p style="text-indent:-2em;margin-left:6em;">- Platelet count ≥140,000/mm<sup>3</sup></p>
<p style="text-indent:-2em;margin-left:6em;">- Hemoglobin ≥12 g/dL</p>
<p style="text-indent:-2em;margin-left:6em;">- ANC ≥1,500/mm<sup>3</sup></p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F56222845"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease, acute, treatment, steroid-refractory:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 59 mL/minute and any platelet count: Initial: 5 mg once daily. Additional dose adjustments should be made with frequent monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease (ESRD) (CrCl &lt;15 mL/minute) on dialysis and any platelet count: Initial dose: 5 mg once after dialysis; additional dose adjustments should be made with careful monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD (CrCl &lt;15 mL/minute) not requiring dialysis: Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease, chronic, treatment, refractory:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 59 mL/minute and any platelet count: Initial: 5 mg twice daily. Additional dose adjustments should be made with frequent monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease (ESRD) (CrCl &lt;15 mL/minute) on dialysis and any platelet count: Initial dose: 10 mg once after dialysis; additional dose adjustments should be made with careful monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD (CrCl &lt;15 mL/minute) not requiring dialysis: Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Myelofibrosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 59 mL/minute and platelets &gt;150,000/mm<sup>3</sup>: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 59 mL/minute and platelets 100,000 to 150,000/mm<sup>3</sup>: Initial dose: 10 mg twice daily; additional dose adjustments should be made with careful monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 59 mL/minute and platelets 50,000 to &lt;100,000/mm<sup>3</sup>: Initial dose: 5 mg once daily; additional dose adjustments should be made with careful monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 59 mL/minute and platelets &lt;50,000/mm<sup>3</sup>: Avoid use.</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD (CrCl &lt;15 mL/minute) on dialysis and platelets 100,000 to 200,000/mm<sup>3</sup>: Initial dose: 15 mg once after dialysis; administer subsequent doses after dialysis on dialysis days. Additional dose adjustments should be made with frequent monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD (CrCl &lt;15 mL/minute) on dialysis and platelets &gt;200,000/mm<sup>3</sup>: Initial dose: 20 mg once after dialysis; administer subsequent doses after dialysis on dialysis days. Additional dose adjustments should be made with frequent monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD not requiring dialysis: Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Polycythemia vera:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 59 mL/minute and any platelet count: Initial: 5 mg twice daily. Additional dose adjustments should be made with frequent monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD (CrCl &lt;15 mL/minute) on dialysis and any platelet count: Initial dose: 10 mg once after dialysis; additional dose adjustments should be made with careful monitoring</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD (CrCl &lt;15 mL/minute) not requiring dialysis: Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis is not expected to enhance the elimination of ruxolitinib.</p></div>
<div class="block doha drugH1Div" id="F56222843"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease, acute, treatment, steroid-refractory:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Preexisting hepatic impairment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild to severe impairment (based on NCI criteria) without liver acute graft-versus-host disease (aGVHD) and any platelet count: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Stage 1, 2, or 3 liver aGVHD and any platelet count: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Stage 4 liver aGVHD and any platelet count: 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatoxicity during treatment (refer to "Dosing: Adjustment for Toxicity" for aGVHD dosage reduction levels):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Total bilirubin elevation <b>without</b> liver GVHD:</p>
<p style="text-indent:-2em;margin-left:8em;">Total bilirubin 3 to 5 times ULN: Continue ruxolitinib at 1 dose level lower until recovery.</p>
<p style="text-indent:-2em;margin-left:8em;">Total bilirubin &gt;5 to 10 times ULN: Interrupt ruxolitinib treatment for up to 14 days. When bilirubin recovers to ≤1.5 times ULN, then resume at current dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Total bilirubin &gt;10 times ULN: Interrupt ruxolitinib treatment for up to 14 days. When bilirubin recovers to ≤1.5 times ULN, then resume at 1 dose level lower.</p>
<p style="text-indent:-2em;margin-left:6em;">Total bilirubin elevation <b>with</b> liver GVHD: Total bilirubin &gt;3 times ULN: Continue ruxolitinib at 1 dose level lower until recovery.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease, chronic, treatment, refractory:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Preexisting hepatic impairment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild to severe impairment (based on NCI criteria) without liver chronic graft-versus-host disease (cGVHD) and any platelet count: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Score 1 or 2 liver cGVHD and any platelet count: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Score 3 liver cGVHD and any platelet count: Monitor blood counts more frequently for toxicity and modify the ruxolitinib dose for adverse reactions if they occur.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatoxicity during treatment (refer to "Dosing: Adjustment for Toxicity" for cGVHD dosage reduction levels):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Total bilirubin 3 to 5 times ULN: Continue ruxolitinib at 1 dose level lower until recovery. If resolved within 14 days, then increase by 1 dose level. If not resolved within 14 days, maintain the decreased dose level.</p>
<p style="text-indent:-2em;margin-left:6em;">Total bilirubin &gt;5 to 10 times ULN: Interrupt ruxolitinib treatment for up to 14 days until resolved, then resume at the current dose upon recovery. If not resolved within 14 days, then resume at 1 dose level lower upon recovery.</p>
<p style="text-indent:-2em;margin-left:6em;">Total bilirubin &gt;10 times ULN: Interrupt ruxolitinib treatment for up to 14 days until resolved, then resume at 1 dose level lower upon recovery. If not resolved within 14 days, discontinue ruxolitinib.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Myelofibrosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to severe impairment (Child-Pugh class A, B, or C) and platelets &gt;150,000/mm<sup>3</sup>: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to severe impairment (Child-Pugh class A, B, or C) and platelets 100,000 to 150,000/mm<sup>3</sup>: Initial dose: 10 mg twice daily; additional dose adjustments should be made with careful monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to severe impairment (Child-Pugh class A, B, or C) and platelets 50,000 to &lt;100,000/mm<sup>3</sup>: Initial dose: 5 mg once daily; additional dose adjustments should be made with careful monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to severe impairment (Child-Pugh class A, B, or C) and platelets &lt;50,000/mm<sup>3</sup>: Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Polycythemia vera:</b> Mild to severe impairment (Child-Pugh class A, B, or C) and any platelet count: Initial dose: 5 mg twice daily; additional dose adjustments should be made with careful monitoring.</p></div>
<div class="block adr drugH1Div" id="F56222885"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (5% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesteremia (17% to 88%), hypertriglyceridemia (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (10% to 15%), nausea (6% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (72% to 96%; grades 3/4: ≤34%), bruise (23%), hemorrhage (12%), neutropenia (3% to 19%; grades 3/4: ≤12%), thrombocytopenia (27% to 70%; grades 3/4: ≤20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (25% to 73%), increased serum aspartate aminotransferase (17% to 65%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (45%), viral infection (28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (15% to 18%), fatigue (13%), headache (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle spasm (12%), musculoskeletal pain (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (13%), dyspnea (11% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain (6% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (8%), flatulence (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (6% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster infection (2% to 6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Basal cell carcinoma of skin, Merkel cell carcinoma, skin carcinoma, squamous cell carcinoma of skin</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased LDL cholesterol</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Serious infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Progressive multifocal leukoencephalopathy</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Exacerbation of hepatitis B</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes simplex infection (reactivation and/or dissemination)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Insomnia (Verstovsek 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Tuberculosis</p></div>
<div class="block coi drugH1Div" id="F56222882"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Hypersensitivity to ruxolitinib or any component of the formulation or container; history of or current progressive multifocal leukoencephalopathy.</p></div>
<div class="block war drugH1Div" id="F56222883"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac effects: The risk for major adverse cardiovascular events, including cardiovascular death, myocardial infarction, and stroke was increased with use of another Janus kinase (JAK)-inhibitor (as compared to tumor necrosis factor [TNF] blockers) in patients treated for rheumatoid arthritis (not an approved indication for ruxolitinib). Inform patients of the symptoms of serious cardiovascular events.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic toxicity: Hematologic toxicity, including thrombocytopenia, anemia and neutropenia may occur with ruxolitinib. Thrombocytopenia and neutropenia (ANC &lt;500/mm<sup>3</sup>) are generally reversible with treatment interruption or dose reduction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Serious bacterial, mycobacterial (including tuberculosis), fungal, and/or viral infections have occurred. Active serious infections should be resolved prior to ruxolitinib treatment initiation. Progressive multifocal leukoencephalopathy (PML) has been reported. Hepatitis B viral load (HBV-DNA titer) increases (with and without associated ALT or AST elevations) have been reported with ruxolitinib in patients with chronic hepatitis B infection, although the effect of ruxolitinib is unknown. Herpes zoster infection, as well as herpes simplex virus reactivation and/or dissemination, have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lipid abnormalities: Ruxolitinib has been associated with increases in lipid parameters (eg, total cholesterol, LDL cholesterol, and triglycerides).</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancy: Nonmelanoma skin cancers (basal cell, squamous cell, and Merkel cell carcinoma) have been reported in patients who have received ruxolitinib. The risk for lymphoma and other malignancies (excluding nonmelanoma skin cancer) was increased with use of another JAK-inhibitor (as compared to TNF blockers) in patients treated for rheumatoid arthritis (not an approved indication for ruxolitinib). Patients who are current or past smokers are at additional increased risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombosis: The risk for thrombosis, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis, has increased with use of another JAK-inhibitor (as compared to TNF blockers) in patients treated for rheumatoid arthritis (not an approved indication for ruxolitinib).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal syndrome: Acute relapse of myelofibrosis symptoms (eg, fever, respiratory distress, hypotension, DIC, multiorgan failure), splenomegaly, worsening cytopenias, hemodynamic compensation, and septic shock-like syndrome have been reported with treatment tapering or discontinuation (Tefferi 2011). Symptoms generally return over approximately 1 week. Patients should not interrupt/discontinue treatment without consulting healthcare provider.</p></div>
<div class="block foc drugH1Div" id="F56222924"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jakafi: 5 mg, 10 mg, 15 mg, 20 mg, 25 mg</p></div>
<div class="block geq drugH1Div" id="F56222870"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F56222926"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Jakafi Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $343.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $343.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $343.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $343.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $343.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56222974"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jakavi: 5 mg, 10 mg, 15 mg, 20 mg</p></div>
<div class="block exp drugH1Div" id="F56222927"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;">A suspension for nasogastric administration may be prepared with tablets. Place one tablet into ~40 mL water; stir for approximately 10 minutes. Administer within 6 hours after preparation.</p>
<div class="reference">Jakafi (ruxolitinib) [prescribing information]. Wilmington, DE: Incyte Corporation; May 2019.</div>
</div>
<div class="block accres drugH1Div" id="F56222862"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Available through specialty/network pharmacies. Further information may be obtained from the manufacturer, Incyte, at 1-855-452-5234 or at www.Jakafi.com.</p></div>
<div class="block admp drugH1Div" id="F56222842"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with or without food. May also administer through nasogastric (NG) tube (≥8 Fr) if unable to ingest tablets.</p>
<p style="text-indent:-2em;margin-left:2em;">NG tube (≥8 Fr) administration: Suspend 1 tablet in ~40 mL water and stir for ~10 minutes; administer with appropriate syringe within 6 hours after dispersion; rinse NG tube with ~75 mL water (effect of enteral tube feedings [eg, enteral formulas] on ruxolitinib exposure has not been evaluated).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i> If a dose is missed, do <b>not</b> administer an additional dose; return to the usual dosing schedule.</p></div>
<div class="block adm drugH1Div" id="F56222914"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> May be administered with or without food. If a dose is missed, return to the usual dosing schedule and do <b>not</b> administer an additional dose.</p>
<p style="text-indent:-2em;margin-left:2em;">If unable to ingest tablets, may administer through a nasogastric (NG) tube (≥8 Fr): Suspend 1 tablet in ~40 mL water and stir for ~10 minutes and administer (within 6 hours after dispersion) with appropriate syringe; rinse NG tube with ~75 mL water (effect of enteral tube feeding on ruxolitinib exposure has not been evaluated).</p></div>
<div class="block sts drugH1Div" id="F56222896"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).</p></div>
<div class="block usep drugH1Div" id="F56222980"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of steroid-refractory acute graft-versus-host disease (GVHD) and chronic GVHD after failure of 1 or 2 lines of systemic therapy treatments (FDA approved in ages ≥12 years and adults); treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis, and postessential thrombocythemia myelofibrosis (FDA approved in adults); treatment of polycythemia vera with an inadequate response to or intolerance to hydroxyurea (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F56222860"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ruxolitinib may be confused with cabozantinib, fedratinib, pacritinib, PONATinib, regorafenib, ripretinib, riTUXimab, rucaparib, tofacitinib.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F56222891"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F56222888"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): May increase the serum concentration of Ruxolitinib (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May increase serum concentrations of the active metabolite(s) of Ruxolitinib (Systemic). CYP3A4 Inducers (Strong) may decrease the serum concentration of Ruxolitinib (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Ruxolitinib (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ruxolitinib (Systemic). Management: This combination should be avoided under some circumstances; dose adjustments may be required in some circumstances and depend on the indication for ruxolitinib. See monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: May increase the serum concentration of Ruxolitinib (Systemic). Management: Avoid fluconazole doses over 200 mg/day in combination with ruxolitinib. Dose adjustments are required in some circumstances. See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F56222895"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Grapefruit juice may increase the effects of ruxolitinib. Management: Avoid grapefruit juice.</p></div>
<div class="block dic drugH1Div" id="F56222913"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Avoid grapefruit juice (may increase the effects of ruxolitinib).</p></div>
<div class="block pri drugH1Div" id="F56222879"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on data from animal reproduction studies, ruxolitinib may cause fetal harm if administered during pregnancy. Use of ruxolitinib in pregnant patients is not recommended; other agents are preferred for management of polycythemia vera and myeloproliferative disease (Gerds 2017; Kiladjian 2015).</p></div>
<div class="block mopp drugH1Div" id="F56222981"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC (baseline, every 2 to 4 weeks until dose stabilized, then as clinically indicated; monitor blood counts more frequently in patients with stage 3 or 4 liver graft-versus-host disease [GVHD]), lipid parameters (8 to 12 weeks after ruxolitinib initiation and as appropriate thereafter), renal function, hepatic function (including bilirubin in patients with GVHD; prior to treatment and every 2 to 4 weeks until dose stabilized, then as clinically indicated). Monitor hepatitis B viral load (HBV-DNA titer) in patients with chronic hepatitis B infection. Perform periodic skin examinations. Monitor for signs/symptoms of infection and secondary malignancy. Perform tuberculin skin test (prior to initiation); patients at higher risk for tuberculosis (prior residence/travel to countries with a high tuberculosis prevalence, close contacts with active tuberculosis, or history of latent or active tuberculosis where adequate treatment course cannot be confirmed) should be tested for latent infection. Monitor for signs/symptoms of thrombosis and for major adverse cardiovascular events, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F56222897"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ruxolitinib is a kinase inhibitor which selectively inhibits Janus Associated Kinases (JAKs), JAK1 and JAK2. JAK1 and JAK2 mediate signaling of cytokine and growth factors responsible for hematopoiesis and immune function; JAK mediated signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors which leads to modulation of gene expression. In myelofibrosis and polycythemia vera, JAK1/2 activity is dysregulated; ruxolitinib modulates the affected JAK1/2 activity. JAK-STAT signaling is involved with the regulation of the development, proliferation, and activation of immune cell types important to GVHD pathogenesis; an animal model suggests that ruxolitinib may lead to decreased expression of inflammatory cytokines in colon homogenates and decreased immune cell infiltration in the colon.</p></div>
<div class="block phk drugH1Div" id="F56222898"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset:</p>
<p style="text-indent:-2em;margin-left:4em;">Acute graft-versus-host disease (GVHD): Median time to response: 1.5 weeks (range: 1 to 11 weeks) (Zeiser 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">Chronic GVHD: Median time to response: 3 weeks (range: 1 to 25 weeks) (Zeiser 2015); responses were observed within 2 weeks of ruxolitinib initiation in another study (Khoury 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Myelofibrosis: 72 L; Polycythemia vera: 75 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~97%; primarily to albumin.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic, primarily via CYP3A4 (and minimally CYP2C9); forms active metabolites responsible for 20% to 50% of activity.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Ruxolitinib: ~3 hours; Ruxolitinib + metabolites: ~5.8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Within 1 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (74%, &lt;1% as unchanged drug); feces (22%, &lt;1% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Myelofibrosis: 17.7 to 22.1 L/hour; polycythemia vera: 12.7 L/hour; acute graft-versus-host disease: 11.8 L/hour; chronic graft-versus-host disease: 9.7 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F56222899"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: The total AUC of ruxolitinib (and active metabolites) increased by 1.3-, 1.5-, and 1.9-fold in subjects with mild, moderate, or severe renal impairment, respectively, compared to those with CrCl ≥90 mL/minute. Total AUC of ruxolitinib and active metabolites increased 1.6-fold in subjects with ESRD requiring dialysis (compared to those with CrCl ≥90 mL/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Ruxolitinib AUC increased by 1.9-, 1.3-, and 1.7-fold in subjects with Child-Pugh class A, Child-Pugh class B, or Child-Pugh class C hepatic impairment, respectively, compared to subjects with normal hepatic function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56222929"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Jakavi | Ruxolitinib</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Jakafi</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Jakavi</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-24174625">
<a name="24174625"></a>Cervantes F, Vannucchi AM, Kiladjian JJ, et al; COMFORT-II investigators. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. <i>Blood</i>. 2013;122(25):4047-4053.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/24174625/pubmed" id="24174625" target="_blank">24174625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23677817">
<a name="23677817"></a>Chen X, Williams WV, Sandor V, Yeleswaram S. Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF). <i>J Clin Pharmacol</i>. 2013;53(7):721-730.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/23677817/pubmed" id="23677817" target="_blank">23677817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28095380">
<a name="28095380"></a>Gerds AT, Dao KH. Polycythemia vera management and challenges in the community health setting. <i>Oncology</i>. 2017;92(4):179-189. doi:10.1159/000454953<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/28095380/pubmed" id="28095380" target="_blank">28095380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22375970">
<a name="22375970"></a>Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK Inhibition With Ruxolitinib versus Best Available Therapy for Myelofibrosis. <i>N Engl J Med</i>. 2012;366(9):787-798. doi:10.1002/jcph.102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/22375970/pubmed" id="22375970" target="_blank">22375970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jakafi.1">
<a name="Jakafi.1"></a>Jakafi (ruxolitinib) [prescribing information]. Wilmington, DE: Incyte Corporation; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jakavi.1">
<a name="Jakavi.1"></a>Jakavi (ruxolitinib) [product monograph]. Montreal, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28344057">
<a name="28344057"></a>Khandelwal P, Teusink-Cross A, Davies SM, et al. Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients. <i>Biol Blood Marrow Transplant</i>. 2017;23(7):1122-1127. doi:10.1016/j.bbmt.2017.03.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/28344057/pubmed" id="28344057" target="_blank">28344057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25993201">
<a name="25993201"></a>Kiladjian JJ. Current therapies and their indications for the Philadelphia-negative myeloproliferative neoplasms. <i>Am Soc Clin Oncol Educ Book</i>. 2015:389-396. doi:10.14694/EdBook_AM.2015.35.e389<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/25993201/pubmed" id="25993201" target="_blank">25993201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23423753">
<a name="23423753"></a>Mesa RA, Gotlib J, Gupta V, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. <i>J Clin Oncol</i>. 2013;31(10):1285-1292.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/23423753/pubmed" id="23423753" target="_blank">23423753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21480207">
<a name="21480207"></a>Mesa RA, Kantarjian H, Tefferi A, et al. Evaluating the Serial Use of the Myelofibrosis Symptom Assessment Form for Measuring Symptomatic Improvement: Performance in 87 Myelofibrosis Patients on a JAK1 and JAK2 Inhibitor (INCB018424) Clinical Trial. <i>Cancer</i>. 2011;117(21):4869-4877.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/21480207/pubmed" id="21480207" target="_blank">21480207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: a clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21602517">
<a name="21602517"></a>Shi JG, Chen X, Emm T, et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. <i>J Clin Pharmacol</i>. 2012;52(6):809-818.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/21602517/pubmed" id="21602517" target="_blank">21602517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20699411">
<a name="20699411"></a>Shilling AD, Nedza FM, Emm T, et al. Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans. <i>Drug Metab Dispos</i>. 2010;38(11):2023-2031.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/20699411/pubmed" id="20699411" target="_blank">20699411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22034658">
<a name="22034658"></a>Tefferi A, Pardanani A. Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis. <i>Mayo Clin Proc</i>. 2011;86(12):1188-1191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/22034658/pubmed" id="22034658" target="_blank">22034658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21995409">
<a name="21995409"></a>Tefferi A, Litzow MR, Pardanani A. Long-Term Outcome of Treatment With Ruxolitinib in Myelofibrosis. <i>N Engl J Med </i>.2011;365(15):1455-1457.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/21995409/pubmed" id="21995409" target="_blank">21995409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25629741">
<a name="25629741"></a>Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. <i>N Engl J Med</i>. 2015;372(5):426-435.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/25629741/pubmed" id="25629741" target="_blank">25629741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22718840">
<a name="22718840"></a>Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. <i>Blood</i>. 2012;120(6):1202-1209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/22718840/pubmed" id="22718840" target="_blank">22718840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20843246">
<a name="20843246"></a>Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. <i>N Engl J Med</i>. 2010;363(12):1117-1127.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/20843246/pubmed" id="20843246" target="_blank">20843246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22375971">
<a name="22375971"></a>Verstovsek S, Mesa RA, Gotlib J, et al .A Double Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. <i>N Engl J Med</i>. 2012;366(9):799-807.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/22375971/pubmed" id="22375971" target="_blank">22375971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24258498">
<a name="24258498"></a>Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. <i>Cancer</i>. 2014;120(4):513-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/24258498/pubmed" id="24258498" target="_blank">24258498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26228813">
<a name="26228813"></a>Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. <i>Leukemia</i>. 2015;29(10):2062-2068. doi: 10.1038/leu.2015.212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/26228813/pubmed" id="26228813" target="_blank">26228813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34260836">
<a name="34260836"></a>Zeiser R, Polverelli N, Ram R, et al; REACH3 Investigators. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. <i>N Engl J Med</i>. 2021;385(3):228-238. doi:10.1056/NEJMoa2033122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/34260836/pubmed" id="34260836" target="_blank">34260836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32320566">
<a name="32320566"></a>Zeiser R, von Bubnoff N, Butler J, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. <i>N Engl J Med</i>. 2020;382(19):1800-1810. doi:10.1056/NEJMoa1917635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ruxolitinib-systemic-pediatric-drug-information/abstract-text/32320566/pubmed" id="32320566" target="_blank">32320566</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 132790 Version 59.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
